Interleukin 35 promotes progression of hepatocellular carcinoma by recruiting neutrophils
Our data show that the high expression of IL-35 in patients with HCC is an important tumor promoter. Combined treatment with anti-IL-35 and anti-PD1 antibodies have potential therapeutic effect against HCC.
Authors
- Sun Guo-qiang
- Jinlong Huang (ORCID: https://orcid.org/0000-0002-4179-5001)
- Sun Bao-ye
- Zhu-Tao Wang
- Cheng Zhou (ORCID: https://orcid.org/0000-0002-3106-5160)
- Yang Zhang-fu
- Yong Yi (ORCID: https://orcid.org/0000-0003-2736-4931)
- Wei Gan
- Shuang-Jian Qiu
Institutions
- Fudan University (CN)
- Zhongshan Hospital (CN)
- Ministry of Education (ET)
Publication Details
- Journal
- Translational Oncology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1016/j.tranon.2025.102630
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00